- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Robert Wood: Even Treatment Failures Move the Food Allergy Field Forward
Even when there are treatment failures, the knowledge gained through food allergy studies helps to move the field forward, explained Robert A. Wood, MD, director, Pediatric Allergy and Immunology, Johns Hopkins Medicine; 2018-2019 president, American Academy of Allergy, Asthma, and Immunology (AAAAI).
Even when there are treatment failures, the knowledge gained through food allergy studies helps to move the field forward, explained Robert A. Wood, MD, director, Pediatric Allergy and Immunology, Johns Hopkins Medicine; 2018-2019 president, American Academy of Allergy, Asthma, and Immunology (AAAAI).
Transcript
What lessons have you learned from the patients and their families in your food allergy studies, even from those that don’t respond to the therapy?
The lessons really are the data that comes from the study for the most part. The families that join studies tend to be highly committed to the entire experience. The kids are remarkably resilient and put up with reactions and food challenges and all those sorts of things.
The knowledge gained is what moves the field forward, and it ranges from tremendous success, where someone is virtually, completely desensitized—not cured, but they can eat food as they wish—to the 15% or so of patients who are complete treatment failures.
And then, long-term the results are, to me, a little bit discouraging. And we’re presenting here at this meeting [2019 AAAAI Annual Meeting], a long-term follow-up of our peanut studies, and over half of all the patients who we thought were successfully treated had electively gone back to strictly avoiding peanuts because they thought life was easier avoiding peanuts than taking a daily dose of peanut.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
